ANDREW FADDEN

Vice President and Head of Corporate Development, Enara Bio

Andrew Fadden is Vice President and Head of Corporate Development at Enara Bio. He joined Enara Bio in 2019 and has over 14 years of drug development, corporate development and leadership experience in the biotech and pharmaceutical industry.
Previously, Andrew was a Director in the Program Leadership Group at Immunocore, where he led multiple early-phase programs from discovery research into clinical development. He was also a key part of the team that agreed a clinical-stage, co-development partnership with Genentech. Prior to Immunocore, Andrew was the Global Regulatory Affairs Lead for the Oncology Portfolio at Vertex Pharmaceuticals, and has held positions of increasing responsibility in Global Regulatory Affairs and Global Development Teams at UCB and GlaxoSmithKline.

Andrew received an MA in Molecular and Cellular Biochemistry at the University of Oxford and he has a PhD from University College London following research at Cancer Research UK’s London Research Institute. Andrew also holds an Executive MBA (with Distinction) from Warwick Business School.